{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:55:37Z","timestamp":1791269737173,"version":"4.1.0"},"reference-count":30,"publisher":"American Psychiatric Association Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.1176\/appi.ajp.20241186","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:00:12Z","timestamp":1770181212000},"page":"183-192","source":"Crossref","is-referenced-by-count":11,"title":["Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial"],"prefix":"10.1176","volume":"183","author":[{"given":"Inder","family":"Kaul","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sauder","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejendra","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[{"name":"Community Clinical Research, Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Marcus","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sawchak","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Brannan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S225643"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2022.100249"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2021.100217"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1007"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.06091591"},{"key":"e_1_3_3_11_2","unstructured":"Kavoussi R Miller AC Breier A: Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects. Presented at the 2017 American Society for Clinical Psychopharmacology annual meeting May 31\u2013June 3 2017 Miami FL"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-024-00525-6"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15497"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_18_2","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan DV","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20):22\u201333","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_3_21_2","first-page":"534","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338","author":"Guy W","year":"1976","unstructured":"Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534\u2013537"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000291514"},{"key":"e_1_3_3_23_2","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338","author":"Guy W","year":"1976","unstructured":"Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218\u2013222"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2022.09.012"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.04.009"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001376"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000220"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy002"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4450-3"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r07539"},{"key":"e_1_3_3_31_2","unstructured":"Kaul I Claxton A Sauder C et al: Long-term safety tolerability and efficacy of xanomeline and trospium chloride in people with schizophrenia: results from the 52-week open-label EMERGENT-5 trial (Poster 67). Presented at Psych Congress October 29\u2013November 2 2024"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:00:25Z","timestamp":1772773225000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.20241186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1176\/appi.ajp.20241186"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.20241186","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}